Guggenheim assumed coverage of Nuvalent (NUVL) with a Buy rating and price target of $122, up from $105.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NUVL:
- Nuvalent initiated with an Outperform at Raymond James
- Nuvalent initiated with an Overweight at Piper Sandler
- Nuvalent Reports Q2 2025 Financials and Pipeline Progress
- Nuvalent’s Promising Drug Pipeline and Strategic Trials Drive Buy Rating
- Nuvalent’s Promising Developments and Strong Financial Position Justify Buy Rating